A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study.

Richard F RiedelKarla V BallmanYao LuSteven AttiaElizabeth T LoggersKristen N GanjooMichael B LivingstonWarren ChowJennifer WrightJohn H WardDaniel RushingScott H OkunoDamon R ReedDavid A LiebnerVicki L KeedyLeo MascarenhasLara E DavisChristopher RyanDenise K ReinkeRobert G Maki

Published in: The oncologist (2020)

Regorafenib did not appear to improve PFS in treatment-refractory liposarcoma. No new significant safety signals were observed.

Keyphrases

placebo controlled
double blind
phase ii study
clinical trial
squamous cell carcinoma
open label
study protocol
randomized controlled trial
radiation therapy
smoking cessation